[Pathogenetic therapy of spasticity].
Kasatkin
D S
DS
D000328:Adult; D000368:Aged; D000818:Animals; D002547:Cerebral Palsy / Q000188:drug therapy; D002648:Child; D018849:Controlled Clinical Trials as Topic; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008559:Memantine / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D009123:Muscle Hypotonia / Q000503:physiopathology; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D009129:Muscle Tonus / Q000502:physiology*; D009209:Myofascial Pain Syndromes / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000627:therapeutic use; D051381:Rats
D015259:Dopamine Agents; D009125:Muscle Relaxants, Central; D009465:Neuromuscular Agents; D003620:Dantrolene; D008559:Memantine